These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35181939)

  • 1. Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report.
    Mostmans Y; Van Gysel J; Vanden Nest H; Mervillie K; Richert B; Clevenbergh P
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e548-e550. PubMed ID: 35181939
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
    Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
    J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
    [No Abstract]   [Full Text] [Related]  

  • 3. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic Alterations Related to Intralesional Glucantime® Treatments: A Potentially Severe Adverse Event.
    García Bracamonte B; Burillo Martínez S; Morales Raya C; Ortiz Romero P
    Actas Dermosifiliogr; 2022; 113(7):742-744. PubMed ID: 35331726
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.
    Salmanpour R; Razmavar MR; Abtahi N
    Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
    Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
    Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N; Sagheer F; Paracha MM; Khan AQ; Naseem S; Wasim M
    J Ayub Med Coll Abbottabad; 2022; 34(4):849-853. PubMed ID: 36566412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
    Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A family cluster of cutaneous Leishmania major infection unresponsive to intralesional meglumine antimonial: Case reports.
    Ziaee M; Ghatee MA; Taylor WR; Karamian M
    Indian J Med Microbiol; 2022; 40(3):451-454. PubMed ID: 35680474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized leishmaniasis treated with intralesional meglumine antimoniate.
    Villela-Segura U; Proy-Trujillo H; Ilizaliturri-Flores I; Leal-Ascencio VJ; Eljure-López N
    J Dtsch Dermatol Ges; 2020 Sep; 18(9):1025-1027. PubMed ID: 32656933
    [No Abstract]   [Full Text] [Related]  

  • 13. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
    Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
    Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T; Lehn N; Landthaler M; Stolz W
    Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
    Sadeghian G; Nilfroushzadeh MA; Iraji F
    Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
    Vargas-Gonzalez A; Canto-Lara SB; Damian-Centeno AG; Andrade-Narvaez FJ
    Am J Trop Med Hyg; 1999 Dec; 61(6):960-3. PubMed ID: 10674678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
    Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
    Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.